Adam Resnick

Newly developed technology is advancing the ability of researchers to gain important insight from small clinical specimens.

Using cell lines provided by the Children’s Brain Tumor Network, researchers will attempt to build resources used to develop effective treatments and predict the treatment outcomes of pediatric brain tumor patients.

RNA-binding proteins (RBP) may play critical roles in medulloblastoma development studying their roles will provide additional direct and indirect targets for the treatment of these tumors and beyond. Researchers will utilize cell lines provided by the Children’s Brain Tumor Network in an effort to identify new targets in the pediatric forms of these tumors.

Medulloblastoma is a tumor with many subtypes and noninvasive diagnostic tools are needed to accelerate diagnosis. Using rare samples made available through the Children’s Brain Tumor Network, researchers will analyze the use of noninvasive methods for tumor classification.

Many pediatric brain tumors are unable to be removed in surgery, requiring the development of new effective therapies. Using RNA samples provided by CBTN, researchers are producing important characterization of the tumors and biomarker data to be used by researchers around the world in the pursuit of such new approaches.

Integrative research is needed to advance the treatment options for pediatric cancers. Researchers will analyze data provided through the Pediatric Brain Tumor Atlas in an effort to identify new opportunities in the treatment of pediatric cancers.

Information regarding the mutations of genes in pediatric brain tumors is integral in developing new diagnostics and treatments. Researchers will use the Pediatric Brain Tumor Atlas to analyze comprehensive genetic information across pediatric brain tumor types, which will be used by researchers in the development of new treatments.

Pediatric meningiomas are extremely rare tumors and are often of an aggressive form unresponsive to available treatments. Specimens from the Pediatric Brain Tumor Atlas will allow researchers to study this rare tumor in an effort to develop targeted therapies.

There is a great need to find new targets for pediatric brain cancer therapeutics, requiring comprehensive analysis of tumor types. Access to the unique dataset available through the Pediatric Brain Tumor Atlas and computational support from CBTN will allow researchers to carry out this research.

A robust resource on the drug response across pediatric cancer types will be helpful to guide clinical decisions. Using samples provided by the Children’s Brain Tumor Network, researchers will create and share this important data resource.

Low grade gliomas are often associated with the genetic disorder neurofibromatosis type 1 and research is needed to develop targeted therapies for such tumors. The Children’s Brain Tumor Network is providing researchers with rare samples necessary to accelerate progress in the treatment of NF1-LGGs.

Tumor classification through imaging is an important part of pediatric cancer diagnosis and treatment. Researchers will investigate tumor imagery and genomic data provided by the Children’s Brain Tumor Network in an effort to advance the accuracy of tumor classification.

Epithelial-to-mesenchymal transition (EMT) derived stem cells and cancer cells share certain common characteristics. Using data from the Pediatric Brain Tumor Atlas, researchers will perform a variety of comprehensive analyses in an effort to better understand the link between the EMT and cancer growth.

The treatment of rare and deadly pediatric brain cancer requires an international effort to increase the impact of new discoveries. Through incorporation of data from the Pediatric Brain Tumor Atlas, researchers seek to develop the Australian Bioinformatics Commons, the largest data sharing initiative ever undertaken in Australia.

Precision oncology can be a challenge for pediatric brain tumors. Researchers will interrogate data from the Pediatric Brain Tumor Atlas in an effort to explain poor outcomes and guide treatments for patients with under-explored mutations.

DNA damage susceptibility in adults has been found to be strongly associated with future cancer diagnosis, could the same be true for pediatric patients? Researchers will investigate data from the Pediatric Brain Tumor Atlas using newly developed algorithms in an effort to answer that question.

Medical imagery is an important part of cancer diagnostics and treatment. Researchers will use medical imagery available through the Pediatric Brain Tumor Atlas to evaluate new anomaly detection methods in an effort to advance individualized cancer diagnostics.

Comprehensive, integrative research is needed to advance the diagnosis and care of patients with high grade glioma (HGG). Using data provided through the Pediatric Brain Tumor Atlas, researchers will search for potential drug targets for the treatment of HGGs.

Human development, disease risk, and response to treatments are often different in males and females. Researchers will interrogate data available through the Pediatric Brain Tumor Atlas to determine whether cancer treatments could be optimized based on such differences.

The identification of germline protein expression in brain cancer cells is pivotal in guiding the development of new treatments.s. Using the Pediatric Brain Tumor Atlas, researchers seek to create an important resource on the details of protein expression across many individual brain cancer types.

Oncogenic fusions involving receptor tyrosine kinases (RTK) provide an excellent opportunity for therapeutic targeting but the clinical and molecular landscape of pediatric RTK-driven gliomas remains largely uncharted. To define clinically-relevant tumor subgroups and assess their prognostic significance, we will evaluate the correlation between molecular and clinical characteristics. This project will provide mechanistic insights into RTK-fused gliomas and enable precision medicine approaches to treat these tumors.

This study will utilize artificial intelligence algorithms to predict underlying mutational status and outcomes for pediatric low grade glioma based on complex brain tumor MRI imaging features.

The treatment of pediatric high grade gliomas could be improved and enhanced with a deeper understanding of their genetic and molecular characteristics. Using specimens from the Children’s Brain Tumor Network, researchers are exploring new therapeutic opportunities for pHGG.

We have not yet discovered why the vast majority of children develop brain cancer. Utilizing CBTN data and Kids First data resources, researchers at CBTN are working to answer questions about the cause of pediatric brain tumors.

The effective treatment of brain tumors requires a robust understanding of their biology. Using rare, high quality neurocytoma samples provided by the Children’s Brain Tumor Network, researchers seek to develop new treatments for this disease.

Oligodendroglioma is a rare brain cancer that has been hard to study due to a lack of available biospecimens. The Children’s Brain Tumor Network will provide researchers with the rare specimens necessary to generate deeper understanding of this malignant tumor.

High grade gliomas can affect patients of all ages, and cross-age group analysis could lead to advancements in care for all populations. Using samples and data provided by the Children’s Brain Tumor Atlas, researchers supported by the NCI seek to improve outcomes for patients experiencing these tumors.

Pediatric brain tumors are the leading cause of disease related death in children. Major factors contributing to treatment failures for children with brain tumors include: i) the lack of comprehensive molecular description of the disease and an associated dearth of integration of the tumors’ biologi

Research into adult cancer has benefited greatly from large scale genomic research. Until now due to the limited resources and availability pediatric brain tumors have not been part of large-scale genomic generation efforts. The CBTN aims to create a comprehensive genomic atlas for use by researchers worldwide to unlock how brain tumors develop, grow, survive, and how they can be treated and cured.